59
Participants
Start Date
September 30, 2006
Primary Completion Date
June 30, 2010
Study Completion Date
June 30, 2013
Bortezomib, Dexamethasone, Rituximab
The combination of bortezomib, dexamethasone and rituximab will be administered in five treatment cycles. Bortezomib will be administered as an iv push over 3 to 5 seconds at a dose of 1.3mg/m2/day on days 1,4,8 and 11 of cycle one. On cycles 2-5 bortezomib will be given at a dose of 1.6mg/m2/day on days 1,8,15 and 22 of each cycle. Only on cycles 2 and 5, following the administration of bortezomib, dexamethasone 40mg IV and rituximab 375mg/m2 IV will be administered. A total of 8 infusions of rituximab will be administered. The administration of bortezomib before rituximab may abrogate the IgM flare phenomenon that occurs frequently after the first course of rituximab.
University of Athens School of Medicine, Athens
Collaborators (1)
University of Athens
OTHER
University of Roma La Sapienza
OTHER
Niguarda Hospital
OTHER
University of Turin, Italy
OTHER
University of Salamanca
OTHER
Hospital Clinic of Barcelona
OTHER
Hotel Dieu Hospital
OTHER
Erasmus Medical Center
OTHER
University Hospital, Toulouse
OTHER
Fondazione IRCCS Policlinico San Matteo di Pavia
OTHER
Laikο General Hospital, Athens
OTHER
Klinikum der Universitaet Muenchen, Grosshadern
OTHER
Aalborg University Hospital
OTHER
Centre Hospitalier de Lens
OTHER
Universitaire Ziekenhuizen KU Leuven
OTHER
Theagenio Cancer Hospital
OTHER_GOV
University of Wuerzburg
OTHER
Skane University Hospital
OTHER
Sahlgrenska University Hospital
OTHER
European Myeloma Network B.V.
NETWORK